Christine du, MD
Transplant Surgery · Allentown, PANPI 1851558860
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,890 of the $2,651 with a category attached, or 71.3%. Gilead accounts for 71.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $1,975 and has fallen 97.1% since, to $58 in 2025.
Across 24 payments — averaging $110.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Veloxis Pharmaceuticals, Inc.$375
- Covidien LP$102
- Integra Lifesciences Corporation$83
- Organox Ltd$58
- AstraZeneca$45
- plus $99 from 6 others
Across 26 payments — averaging $1203.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$31K
What the payments were for
- Consulting fees$1,89071%
- Food & beverage$71627%
- Education$452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $1,890 |
| Veloxis Pharmaceuticals, Inc. | 12 | $375 |
| Covidien LP | 1 | $102 |
| Integra Lifesciences Corporation | 1 | $83 |
| Organox Ltd | 1 | $58 |
| AstraZeneca | 2 | $45 |
| AbbVie | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Merck | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,651 in reported general payments places this provider in the 75th percentile of 41 transplant surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $13,067 |
| Valganciclovir Hcl | 35 | $6,997 |
| Fluconazole | 20 | $2,281 |
| Tacrolimus | 21 | $1,964 |
| Prednisone | 79 | $519 |
| Nystatin | 11 | $437 |
| Famotidine | 25 | $381 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 68 | $300 |
| Tamsulosin Hcl | 17 | $201 |
| Amlodipine Besylate | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Allentown
- George RofaielAllentown$2K
- Patty LiuAllentown$570
- Michael MoritzAllentown$427
- Brian ChenAllentown$85
- Pradip ChakrabartiAllentown$48
- Michael MarvinDanville$143K
- Adam BodzinPhiladelphia$75K
- Peter AbtPhiladelphia$10K
- Anil KotruDanville$8K
- Ira FoxPittsburgh$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.